4D-150
Phase 3- Indications
- Wet age-related macular degeneration, Diabetic macular edema
Company intelligence / Profile preview
Molecular Therapeutics
Emeryville, CA, United States4dmoleculartherapeutics.com ↗
- Ownership
- Private
- Employees
- ~227
- Development stage
- Phase 3
01
Overview
The company has demonstrated positive clinical results with its lead candidates. Notably, 4D‑150 for wet AMD has received RMAT designation from the FDA and is advancing through late-stage trials. Aerosolized 4D‑710 for cystic fibrosis received Rare Pediatric Disease Designation from the FDA. The pipeline covers ophthalmology, pulmonology, and cardiology indications with multiple programs showing promising early to mid-stage data.
- Therapeutic areas
- PulmonologyRare DiseasesOphthalmology
- Modalities
- Gene therapy (AAV vectors)Genetic medicines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
F. Hoffmann-La Roche LtdArbor BiotechnologiesuniQure biopharma B.V.Astellas Gene Therapies
Beyond the preview
Go deeper on Molecular Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Molecular Therapeutics.